Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
10/2000
10/24/2000US6136310 Recombinant anti-CD4 antibodies for human therapy
10/24/2000US6136294 Amino acid stabilized medical aerosol formulation
10/19/2000WO2000061788A2 Poly(dipeptide) as a drug carrier
10/19/2000WO2000061774A2 Bone morphogenic proteins
10/19/2000WO2000061750A2 TYROSINE KINASE SUBSTRATE (Tks) PROTEINS
10/19/2000WO2000061748A1 48 human secreted proteins
10/19/2000WO2000061620A1 49 human secreted proteins
10/19/2000WO2000061608A2 Low-molecular inhibitors of complement proteases
10/19/2000WO2000061604A2 Pharmaceutical compounds
10/19/2000WO2000061596A1 50 human secreted proteins
10/19/2000WO2000061583A1 Xanthine derivatives and analogs as cell signaling inhibitors
10/19/2000WO2000061580A1 Substituted bicyclic heteroaryl compounds as integrin antagonists
10/19/2000WO2000061579A1 New endothelin converting enzyme inhibitors, their production and their use
10/19/2000WO2000061569A1 Adamantane derivatives
10/19/2000WO2000061554A1 1-amino ethylindole derivatives for the treatment of urinary incontinence
10/19/2000WO2000061553A1 2-aminoethyl-indole derivatives, their preparation and therapeutic use
10/19/2000WO2000061541A2 Pharmaceutical compounds
10/19/2000WO2000061233A2 Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
10/19/2000WO2000061232A2 Methods and compositions for the treatment and prevention of lung disease involving a specific rar-beta antagonist
10/19/2000WO2000061221A1 Method of providing cosmetic/medical therapy
10/19/2000WO2000061182A2 Methods and compositions for the treatment and prevention of lung disease involving a selective rar-alpha agonist
10/19/2000WO2000041505A3 Anthranilic acid derivatives
10/19/2000WO2000033872A3 Method of and compositions for immunization with the pseudomonas v antigen
10/19/2000WO2000013702A9 Use of an angiogenic factor for the treatment of microvascular angiopathies
10/19/2000WO2000012720A8 Elongase genes and uses thereof
10/19/2000DE19917505A1 Treating cytokine-mediated diseases, e.g. asthma, allergy, eczema, rheumatoid arthritis or transplant rejection, using new or known maduraphthalazine derivatives
10/19/2000DE19916719A1 Neue ECE-Inhibitoren, ihre Herstellung und Verwendung New ECE inhibitors, their preparation and use
10/19/2000CA2371172A1 50 human secreted proteins
10/19/2000CA2370767A1 49 human secreted proteins
10/19/2000CA2370425A1 Pharmaceutical compounds
10/19/2000CA2369981A1 Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
10/19/2000CA2369728A1 Substituted bicyclic heteroaryl compounds as integrin antagonists
10/19/2000CA2369378A1 Low-molecular inhibitors of complement proteases
10/19/2000CA2369029A1 Poly(dipeptide) as a drug carrier
10/19/2000CA2368829A1 Adamantane derivatives
10/19/2000CA2365917A1 Bone morphogenic proteins
10/19/2000CA2365905A1 48 human secreted proteins
10/19/2000CA2365623A1 Tyrosine kinase substrate (tks) proteins
10/19/2000CA2356128A1 Method of providing cosmetic/medical therapy
10/18/2000EP1044273A2 COMPOSITIONS DERIVED FROM $i(MYCOBACTERIUM VACCAE) AND METHODS FOR THEIR USE
10/18/2000EP1044215A1 Anti-inflammatory phenylalanine derivatives
10/18/2000EP1044211A1 36 human secreted proteins
10/18/2000EP1044201A1 3-substituted adenines via2-thioxanthines
10/18/2000EP1044024A1 Use of pigmented retinal epithelial cells for creation of an immune privilege site
10/18/2000EP1043995A1 INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
10/18/2000EP1043978A1 Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
10/18/2000EP1043973A1 Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant
10/18/2000EP1043930A1 Method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids
10/18/2000EP0850215B1 N-(aroyl)glycine hydroxamic acid derivatives and related compounds
10/18/2000CN1270591A Novel compounds
10/18/2000CN1270590A Novel compounds
10/18/2000CN1270515A Methods and compositions for treating pulmonary disorders using optically pure(S)-salmeterol
10/18/2000CN1270027A Stable aqueous solution of phthalylglutamic acidimide derivative
10/18/2000CN1057455C Chinese medicine composite for curing bronchial disease
10/17/2000US6133479 Phenylethylamine derivatives, processes for preparing them and their use as pharmaceutical compositions
10/17/2000US6133319 For treating an interleukin-8 (il-8) mediated disease by administering a phenyl urea or phenyl thiourea of given formula, such as n-cyclohexyl-n'-(2-hydroxy-4-nitrophenyl)urea
10/17/2000US6133309 Treatment of T-helper cell type 2-mediated immune disease by retinoid antagonists
10/17/2000US6133286 Antagonists; antiinflammatory agents for rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, psoriasis and other skin disorders, e.g., eczema, erythema, pruritus and acne; stroke, reperfusion injury, grafting
10/17/2000US6133272 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
10/17/2000US6133257 Fused polycyclic 2-aminopyrimidine derivatives
10/17/2000US6133247 Method of detecting lung disease
10/17/2000US6133240 Tetrahydronapthalene derivatives and their therapeutic use
10/17/2000US6132987 Polypeptide associated with macrophages; for diagnosis and treatment of inflammation, arthritis and atherosclerosis
10/17/2000US6131566 Metered dose inhaler for albuterol
10/17/2000US6131226 1,4-dihydropyridine compounds as bradykinin antagonists
10/17/2000CA2305893A1 Use of maduraphthalazine derivatives as inhibitors of proinflammatory cytokines
10/17/2000CA2009221C Spray preparations for respiratory tract infections
10/12/2000WO2000060117A2 Prediction of risk of interstitial lung disease
10/12/2000WO2000060082A2 Vesicle associated proteins
10/12/2000WO2000060080A2 Molecules of the immune system
10/12/2000WO2000060051A2 Arpe-19 as a platform cell line for encapsulated cell-based delivery
10/12/2000WO2000059904A2 Compounds and methods to treat cardiac failure and other disorders
10/12/2000WO2000059901A1 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase
10/12/2000WO2000059889A1 α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES
10/12/2000WO2000059886A2 Benzimidazole abd imidazolophyridine derivaties, their preparation and their use as selective modulators of bradykinin b2 (=bk-2) receptors
10/12/2000WO2000059873A1 N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
10/12/2000WO2000059548A1 Polyethyleneimine:dna formulations for aerosol delivery
10/12/2000WO2000059520A1 Herbal compositions and uses for the treatment of allergic reactions
10/12/2000WO2000059506A1 HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD
10/12/2000WO2000059503A1 Pyrrolidine modulators of chemokine receptor activity
10/12/2000WO2000059502A1 Pyrrolidine modulators of chemokine receptor activity
10/12/2000WO2000059495A1 (e)-styryl sulfone anticancer agents
10/12/2000WO2000059483A2 Transdermal drug delivery devices comprising a polyurethane drug reservoir
10/12/2000WO2000059468A1 Drinkable pharmaceutical solution
10/12/2000WO2000059449A2 Purine derivatives having phosphodiesterase iv inhibition activity
10/12/2000WO2000035939A3 Connective tissue growth factor fragments and methods and uses thereof
10/12/2000WO2000033811A3 Improvements in or relating to powders
10/12/2000WO2000025722A3 ENHANCED VACCINES COMPRISING SELF AND NON-SELF IgE PORTIONS OR DIMERIC ANTIGENS
10/12/2000WO1999064039A9 Bradykinin antagonists
10/12/2000WO1999051188A9 A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
10/12/2000CA2373717A1 Pyrrolidine modulators of chemokine receptor activity
10/12/2000CA2369871A1 .alpha.-substituted carboxylic acid derivatives
10/12/2000CA2369544A1 Aryl and heteroaryl fused aminoalkyl-imidazole derivatives:selective modulators of bradykinin b2 receptors
10/12/2000CA2368686A1 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase
10/12/2000CA2368240A1 N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
10/12/2000CA2368185A1 Polyethyleneimine:dna formulations for aerosol delivery
10/12/2000CA2367378A1 Molecules of the immune system
10/12/2000CA2367294A1 Prediction of risk of interstitial lung disease
10/12/2000CA2367143A1 Purine derivatives having phosphodiesterase iv inhibition activity
10/12/2000CA2367100A1 Transdermal drug delivery devices comprising a polyurethane drug reservoir